Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
53.68M | 49.63M | 42.00M | 28.65M | 6.27M | 2.27M | Gross Profit |
25.05M | 22.58M | 4.61M | 3.21M | -1.18M | 1.10M | EBIT |
1.83M | -1.99M | 1.01M | 1.20M | -3.49M | -1.35M | EBITDA |
3.60M | 5.39M | 5.35M | 4.38M | -2.97M | -1.22M | Net Income Common Stockholders |
-1.79M | -1.52M | 55.37K | 1.43M | -3.65M | -1.25M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
21.15M | 19.34M | 24.80M | 8.61M | 12.33M | 1.11M | Total Assets |
46.93M | 48.69M | 48.46M | 26.16M | 19.57M | 3.42M | Total Debt |
1.68M | 2.19M | 2.19M | 2.33M | 780.98K | 0.00 | Net Debt |
-7.47M | -5.15M | -10.61M | -6.28M | -11.55M | -1.11M | Total Liabilities |
10.54M | 12.77M | 12.54M | 9.40M | 4.50M | 714.00K | Stockholders Equity |
36.39M | 35.92M | 35.92M | 16.76M | 15.07M | 2.65M |
Cash Flow | Free Cash Flow | ||||
1.21M | -3.94M | -1.12M | -2.28M | -3.85M | -2.16M | Operating Cash Flow |
9.43M | 3.58M | 4.26M | 4.97M | -1.00M | -1.44M | Investing Cash Flow |
-18.38M | -7.52M | -17.37M | -7.24M | -3.17M | -839.00K | Financing Cash Flow |
9.86M | -1.47M | 17.34M | -1.44M | 15.38M | 2.25M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $11.80B | 10.31 | -7.45% | 2.91% | 7.43% | -7.78% | |
49 Neutral | ― | -4.25% | ― | 14.44% | -2450.00% | ||
$197.52M | ― | -19.32% | ― | ― | ― | ||
$15.54B | 22.64 | 27.30% | 2.15% | ― | ― | ||
$20.01B | 49.17 | 37.91% | 0.92% | ― | ― | ||
€7.95B | 95.32 | 37.44% | 0.62% | ― | ― | ||
$22.86B | 115.83 | 13.73% | 0.18% | ― | ― |
Acusensus Ltd has announced the quotation of 190,000 fully paid ordinary securities on the Australian Securities Exchange (ASX), effective June 4, 2025. This move is part of the company’s strategy to enhance its market presence and operational capacity, potentially impacting its industry positioning by increasing its capital for future growth and development.
The most recent analyst rating on (AU:ACE) stock is a Buy with a A$1.30 price target. To see the full list of analyst forecasts on Acusensus Ltd stock, see the AU:ACE Stock Forecast page.
Acusensus Ltd announced the cessation of 93,136 performance rights due to the lapse of conditional rights, as the conditions for these securities were not met by the deadline of March 31, 2025. This development may impact the company’s capital structure and could have implications for stakeholders, reflecting on the company’s operational adjustments and financial strategy.
Acusensus Ltd has announced the issuance of 92,820 unquoted equity securities, which are ordinary fully paid shares. This move, effective from May 3, 2025, involves the conversion of unquoted options or other convertible securities. The announcement reflects Acusensus’s ongoing financial activities and could potentially impact its market position by increasing its equity base.